WEST HAVEN, Conn. & SAN FRANCISCO--(BUSINESS WIRE)--Cellinfinity Bio, a privately held pioneer biotechnology company developing first/best-in-class cell therapy products against solid tumors and other diseases, today announced the publication of MAJESTIC (mRNA AAV–SB joint engineering of stable therapeutic immune cells), a technology that efficiently and with high cell health introduces genes into human genome, independent of CRISPR and lentiviral methods. This technology is published in Nature Biomedical Engineering on July 10. MAJESTIC has been used to introduce important genes including chimeric antigen receptors into diverse cell types such as CD8 & CD4 T cells, monocytes, NK-cells and induced pluripotent stem cells (iPSCs). Cellinfinity Bio has an exclusive license of the published MAJESTIC technology from Yale University and Professor Sidi Chen’s lab, Founder of Cellinfinity Bio and Associate Professor of Genetics, Yale University.
“Cell engineering with MAJESTIC is a simple two-step process involving: 1) mRNA electroporation to transiently express transposase and 2) AAV vector transduction that introduces novel gene flanked by transposon sequence,” said Sidi Chen. “We show that this technology has strong merits over existing lentiviral-based and CRISPR technologies to generate cell therapy products.”
“Efficient generation of stably engineered immune cells with high viability and activity is critical for cell therapy,” added Premal Patel, M.D., Ph.D., Chief Executive Officer, Cellinfinity. “We intend to employ MAJESTIC in multiple cell types, allowing development of next generation cell therapy against broad ailments.” Cellinfinity holds exclusive rights to the MAJESTIC technology. In addition, the company has licensed other novel cell evolution technologies from Yale, that allow whole-genome gain-of-function and loss-of-function gene screens from the Chen lab.
About Cellinfinity Bio
Cellinfinity Bio is a privately-owned company that is focused on elevating the current standards of cell therapy against solid tumors and other diseases. By leveraging proprietary, directed evolution of cells, Cellinfinity identifies genetic modifications and CAR constructs that substantially improve engineered T-cell and NK-cell function against solid tumors. Cellinfinity develops both first-in-class and best-in-class cell therapy products with the goal to benefit diverse patient populations with unmet medical needs.
